PharmacoEconomics

, Volume 15, Issue 6, pp 641–641 | Cite as

A Review of Quality of Life in Alzheimer’s Disease

Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
  • Marianne Greer
  • Helma Monteban
Correpondence

Keywords

Dementia Adis International Limited Critical Assessment Subjective Quality Additional Criterion 

References

  1. 1.
    Walker MD, Salek SS, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 1: issues in assessing disease impact. Pharmacoeconomics 1998; 14 (5): 499–530PubMedCrossRefGoogle Scholar
  2. 2.
    Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 2: issues in assessing drug effets. Pharmacoeconomics 1998; 14 (6): 613–27PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 1999

Authors and Affiliations

  • Marianne Greer
    • 1
  • Helma Monteban
    • 1
  1. 1.Corporate Health EconomicsBoehringer IngelheimGermany

Personalised recommendations